Rewriting the Cancer Code: Bioelectric Precision Oncology

“If the genome is the score, bioelectric signaling is part of how the orchestra actually plays it. Learn to read that signal and you gain a new way to understand a tumor.”

— Erik A. Nilsen, PhD, Co-founder & Chief Technology Officer

Cancer remains one of medicine's most stubborn problems precisely because it is not one problem. It is a moving target with many origins, it adapts as we treat it, and it routinely outlasts therapies that looked decisive in the lab. For decades the field has read tumors through two powerful lenses: their genetics and their relationship with the immune system. Both have transformed care. Neither, on its own, has been enough.

A third lens is now coming into focus, and it is an electrical one. Every cell maintains a voltage across its membrane, set by the careful traffic of charged ions moving in and out through specialized channels. Healthy tissue keeps that electrochemical order remarkably stable. Tumor tissue does not. Cancer cells tend to sit at abnormal membrane voltages, over-express particular ion channels, and break the calm electrical conversation that normally coordinates neighbors. Taken together, these deviations form a measurable bioelectric state.

Reading the tumor's electrical signature

What makes this exciting from a translational standpoint is that the signature is measurable. Advances in high-resolution imaging, biosensing, and computational modeling now let researchers map electrical behavior at the level of cells and tissues, not just guess at it. That turns a once-abstract property into data — the kind of data you can track over time, compare across patients, and feed into models that look for patterns a human eye would miss.

Cancer cells under the microscope, where altered membrane voltages distinguish diseased tissue from healthy cells. Several electrical approaches are already being studied in oncology. Tumor Treating Fields use low-intensity alternating fields to interfere with the machinery dividing cells rely on. Modulated electro-hyperthermia pairs localized heating with field effects. Newer nano-bioelectric platforms aim to deliver effects deep inside tissue. These are different tools with different mechanisms, but they share a premise: a tumor's electrical behavior is something you can act on.

From discovery to a disciplined pipeline

My job is to turn a premise into a pipeline. Electrome's oncology strategy combines bioelectric mapping with AI-driven analytics and a structured Knowledge Graph that links signals, responses, and outcomes. The goal is not a single device but a repeatable method: characterize a case, match it against what the system has learned, and propose a stimulation protocol tailored to that tumor's electrical fingerprint — then measure, learn, and refine.

“Biology runs on signals, not just chemistry. When we learn to read that code, medicine stops guessing and starts engineering.”

— Erik A. Nilsen, PhD, Co-founder & Chief Technology Officer

I want to be precise about positioning. We see bioelectric therapies as complementary to standard care, designed to work alongside chemotherapy, immunotherapy, surgery, and radiation rather than to replace them. The interesting question is not whether electricity can stand alone against cancer. It is whether reading and gently rewriting a tumor's electrical state can make the therapies we already trust work better, more selectively, and with less collateral cost to the patient.

An illustrated DNA double helix — the genetic layer that bioelectric signaling helps regulate. If the last two decades belonged to genomics and immunology, the next chapter may add electrical signaling as a third cornerstone of precision oncology — not as a slogan, but as another column of evidence on which to base a careful decision.